Healthcare
Carl Zeiss Meditec AG(CZMWF)
Live Price
Offline$29.80
-4.43% today
1Y Change
-55.68%
Window
Jun 25, 2025 β Jun 17, 2026
- Market Cap
- $2.36B
- Revenue Growth
- +7.8%
- EPS Growth
- -19.9%
- Dividend Yield
- 2.0%
Coverage: 246 bars Β· Jun 25, 2025 β Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Carl Zeiss Meditec AG (CZMWF) is a Healthcare stock with a market cap of $2.36B and listed on OTC. The stock last traded around $29.80 and down 55.7% across the available one-year price window (Jun 25, 2025 β Jun 17, 2026). Baseline metrics include revenue growth of +7.8%, EPS growth of -19.9%, a dividend yield of 2.0%. What stands out right now is revenue +7.8%, EPS -19.9%, free cash flow +110.3% with operating margin 13.2% and ROIC 7.7%. The dividend is present but secondary, with a yield around 2.0%. Valuation is more restrained than many high-expectation growth names at P/E 16.7 and price/sales 1.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CZMWF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+7.8% vs +7.6% peer median
Operating Margin
Below sector median
+13.2% vs +19.4% peer median
P/E
Below sector median
16.7 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +7.8% and EPS is at -19.9%, with operating margin around 13.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.0%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | β | -10.7% | -11.2% | -9.2% |
2026 Feb 12, 2026 | β | +0.0% | +2.0% | -7.7% |
2025 Aug 7, 2025 | β | -8.3% | -8.3% | -5.1% |
Benchmark Edge
CZMWF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CZMWF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CZMWF Max Drawdown
-60.71%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CZMWF and SPY.
Company Overview
Carl Zeiss Meditec AG
OTC
Carl Zeiss Meditec AG is a leading medical technology company specializing in ophthalmology and microsurgery solutions. Headquartered in Jena, Germany, and founded in 1846, it operates as a subsidiary of the ZEISS Group, delivering innovative products for diagnosing and treating eye diseases such as ametropia, cataracts, glaucoma, and retinal disorders. Its Ophthalmology segment provides diagnostic tools like slit lamps, refractometers, optical coherence tomography devices, and fundus cameras, alongside surgical equipment including microscopes, biometers, phacoemulsification systems, vitrectomy devices, intraocular lenses, and laser surgery consumables. The Microsurgery segment offers visualization and treatment solutions for neurosurgery, ear-nose-throat procedures, spine, plastic and reconstructive surgery, and dentistry. With a global presence across Europe, North America, and Asia, employing over 5,700 people, Carl Zeiss Meditec AG drives advancements in healthcare through cutting-edge technologies, digital workflow solutions, and AI-integrated systems, enhancing clinical efficiency and patient outcomes in advanced medical equipment sectors.
- Leadership
- Mr. Andreas Pecher
- Employees
- 5.8k
- Street Address
- GΓΆschwitzer StraΓe 51-52, 11 Bermudiana Road
- Mailing
- Jena, MI, 07745
- Region
- Jena, MI, Germany
- Last Updated
- May 11, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 16.7
- EV/EBITDA
- 8.2
- Price/Sales
- 1.1
- Price/Book
- 1.1
Growth
- Revenue
- +7.8%
- EPS
- -19.9%
- Free Cash Flow
- +110.3%
Profitability
- Gross Margin
- 65.8%
- Operating Margin
- 13.2%
- Net Margin
- 6.3%
- ROE
- 6.8%
- ROIC
- 7.7%
Balance Sheet
- Debt/Equity
- 0.29
- Current Ratio
- 2.35
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.